- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02540174
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment (ALTAKRA-1405)
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Study proposal at the first medical consultation for therapeutic management of a first upper aerodigestive tract cancer or lung cancer.
- Selection criteria validation
- Collection of an informed consent
- Randomization :
Arm A: Experimental arm : Addiction consultation to the overall cancer treatment
Arm B: standard of care
The completion of questionnaires , the measurement of exhaled carbone monoxide rate using a CO tester for all patients, and the integrated addiction treatment among patients randomized in Arm A will not interfere with the medical treatment of cancer.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59020
- Oscar Lambret Center
-
Lille, France, 59037
- CHRU of Lille : Albert Calmette Hospital
-
Lille, France, 59037
- CHRU of Lille: Huriez Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a first upper aerodigestive tract cancer or a lung cancer
- Initial cancer treatment
- Aged ≥ 18 and ≤65 years
- Living within a radius of 20 km from the CHRU de Lille/Oscar Lambret Center
- Patient with tobacco addiction: regular smoker = at least 7 cigarettes /week or 1 cigarette/day or short-term ex-smoker = regular smoker who has stopped smoking for less than 1 year from the inclusion date
- Performance status (ECOG/WHO) ≤ 2
- Registered with a social security system
- Informed and signed consent collected before initiation of any study procedures
Exclusion Criteria:
- Previous lung cancer or upper aerodigestive tract cancer
- Previous other cancer < 5 years, evoluting or treated at the inclusion (except uterine cervical carcinoma, basal cell or squamous cell skin carcinoma )
- Mesothelioma and esophageal cancer
- Occasional smoker (less than 7 cigarettes/week or less than 1 cigarette/day)
- Long-term ex-smokers who have stopped smoking for more than 1 year from the inclusion date
- Impossibility to comply with the study procedures due to geographic, social or mental reasons
- Patient under guardianship or tutorship
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
integrated addiction treatment program
|
At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester. At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption. The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program. |
Other: Arm B
standard of care
|
The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in the rates of tobacco abstinent patients at 12 months between arms A and B
Time Frame: 1 year
|
to be a "tobacco abstinent" patient has to :
We compare the two arms in term of tobacco abstinent patients rate. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of alcohol and tobacco consumptions during the study
Time Frame: initial diagnosis, after 3, 6 and 12 months
|
We considere the tobacco and alcohol consumption levels at T0, M3, M6, M12 by the consumption statement and the behaviour change towards tobacco and alcohol, thanks to questionnaires study specific.
|
initial diagnosis, after 3, 6 and 12 months
|
Percentage of tobacco abstinent patients at 12 months
Time Frame: 1 year
|
to be a "tobacco abstinent" patient has to :
We calculate the percentage of tobacco abstinent patients at 12 months considering every patient in the trial. |
1 year
|
Difference in the rates of alcohol and tobacco abstinent patients at 12 months depending on whether or not they have received an addiction treatment
Time Frame: 1 year
|
We use a specialized monitoring in addictology (tobacco/alcohol) at 12 months according to the arms.
The information of a monitoring in addictology will be obtained by the study specific questionnaire at M3, M6, M12
|
1 year
|
Median time between inclusion date and the date of death (from any cause)
Time Frame: 1 year
|
Time until progression.
The time between the date of inclusion and the date of death whatever the cause is.
|
1 year
|
Median progression-free time
Time Frame: 1 year
|
delay between inclusion date and progression date (clinical or radiological)
|
1 year
|
Percentage of Arm A patients who attended the addiction treatment program after the first systematic consultation
Time Frame: 1 year
|
We note for each patient in arm A if they have at least one addictology specialized consultation after the first consultation which is imposed, during the 12 months
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Corinne Vannimenus, MD, CHRU of Lille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALTAKRA-1405
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on integrated addiction treatment program
-
National Institute on Drug Abuse (NIDA)Substance Abuse and Mental Health Services Administration (SAMHSA)UnknownSubstance-Related DisordersUnited States
-
In-Home Addiction Treatment Institute, Inc.Suspended
-
Wake Forest University Health SciencesCompleted
-
Rhode Island HospitalNational Institute of Mental Health (NIMH)CompletedHIV PreventionUnited States
-
Rutgers, The State University of New JerseyNational Institute on Drug Abuse (NIDA)Not yet recruitingSubstance UseUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)Enrolling by invitationBipolar Disorder | Substance Use DisordersUnited States
-
Université de SherbrookeMerck Sharp & Dohme LLC; Novartis; Canadian Institutes of Health Research (CIHR) and other collaboratorsUnknownOsteoporosis With Current Fragility FractureCanada
-
Hiroshima UniversityCompleted
-
Laval UniversityFonds de la Recherche en Santé du QuébecCompleted
-
VA Office of Research and DevelopmentProvidence VA Medical CenterRecruitingBipolar Disorder | Substance Use DisordersUnited States